Regeneron Pharmaceuticals (REGN). Пробитие верхней границы нис | Залим Сохов - ON FLEEK investing
Regeneron Pharmaceuticals (REGN). Пробитие верхней границы нисходящего канала открывает путь к 539$.
В ближайшие недели ожидается одобрение FDA коктейля антител REGEN-COV для лечения больных Covid-19.
Benchmark expects full FDA approval of Regeneron's (REGN) REGEN-COV could be coming within weeks, possibly in both 2.4g and 1.2g doses, citing the 70% reduction in risk of hospitalization or death in a 4,600-patient REGEN-COV randomized placebo-controlled trial in non-hospitalized COVID-19 patients as well as what he sees as "an apparent preference" for Regeneron's cocktail over Eli Lilly's (LLY). Benchmark has a Buy rating and $590 price target on Regeneron shares.
